Novavax faced challenges but gained optimism with new partnership and revenue expectations.

From Nasdaq: 2024-06-29 08:55:00

Novavax (NASDAQ: NVAX) struggled at the start of the year due to issues with its COVID vaccine launch and decreased demand, leading to a decline in revenue. However, a new partnership with Sanofi (NASDAQ: SNY) injected optimism, with Sanofi paying $500 million upfront for the commercialization of Novavax’s COVID vaccine and access to its adjuvant technology. Novavax now expects revenue between $970 million and $1.2 billion for the year, while also developing a combined COVID/flu vaccine and a stand-alone flu vaccine. Despite recent stock gains, Novavax’s future remains uncertain, with success hinging on clinical trial outcomes.



Read more at Nasdaq: Where Will Novavax Be in 1 Year?